Keyword: Pradaxa

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?

Pfizer and Bristol-Myers Squibb’s Eliquis has already secured a sizable lead over its rivals, and now its touting more competitor-topping data.

More signs of trouble for Bayer and J&J's Xarelto? As prescriptions flag, the drugmakers blame stepped-up discounts for its U.S. sales woes.

After testing local market TV last year, Boston Scientific has expanded its TV media run for its Watchman heart implant device.

It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.

The FDA has approved Portola Pharmaceuticals’ factor Xa inhibitor Bevyxxa, but now the company is facing plenty of challenges as it gets the drug off the ground.

Direct oral anticoagulants haven’t made the mark cardiology professionals had hoped in atrial fibrillation patients.

Pfizer and Bristol-Myers face three new lawsuits in New York claiming their big-selling anticoagulant Eliquis ended up hurting patients.

The award-winning computer-generated red fish of Pradaxa just keep swimming—this time through an aquarium in new TV work for Boehringer Ingelheim’s next-gen anticoagulant.

The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week.